Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer
Sponsor: Bayer
Listed as NCT00813293, this PHASE2 trial focuses on Hepatocellular Cancer and remains completed. Sponsored by Bayer, it has been updated 12 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Mar 2019 — Jul 2020 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
- Onyx Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .